Control of gene expression

Patent metadata

Field	Value
Publication number	US-9963698-B2
Application number	US-201314137737-A
Country	US
Kind code	B2
Filing date	Dec 20, 2013
Priority date	Mar 20, 1998
Publication date	May 8, 2018
Grant date	May 8, 2018

Abstract

The present invention relates generally to a method of modifying gene expression and to synthetic genes for modifying endogenous gene expression in a cell, tissue or organ of a transgenic organism, in particular a transgenic animal or plant. More particularly, the present invention utilizes recombinant DNA technology to post-transcriptionally modify or modulate the expression of a target gene in a cell, tissue organ or whole organism, thereby producing novel phenotypes. Novel synthetic genes and genetic constructs which are capable of repressing delaying or otherwise reducing the expression of an endogenous gene or target gene in an organism when introduced thereto are also provided.

First claim

The invention claimed is:

1. A double-stranded DNA construct which is capable of delaying, repressing, or otherwise reducing the expression of a target gene, wherein the double-stranded DNA construct comprises a foreign nucleic acid molecule comprising multiple copies of a nucleotide sequence that is more than 20 nucleotides long and which is substantially identical to a region of the target gene, and wherein the foreign nucleic acid molecule is placed operably under the control of both a first promoter sequence and a second promoter sequence which are each operable in a cell, wherein said promoters are located at the distal and proximal ends of the foreign nucleic acid molecule.

2. The double-stranded DNA construct of claim 1 , wherein the multiple copies are arranged so as to form an inverted repeat sequence between the first promoter sequence and the second promoter sequence.

3. The double-stranded DNA construct of claim 1 , wherein the multiple copies are arranged so as to form an interrupted palindrome sequence between the first promoter sequence and the second promoter sequence.

4. The double-stranded DNA construct of claim 1 , wherein the target gene is in an animal cell.

5. The double-stranded DNA construct of claim 4 , wherein the animal cell is a human cell.

6. The double-stranded DNA construct of claim 4 , wherein the target gene is a gene that is contained within the genome of the animal cell.

7. The double-stranded DNA construct of claim 6 , wherein the animal cell is an invertebrate animal cell.

8. The double-stranded DNA construct of claim 7 , wherein the invertebrate animal cell is an insect cell.

9. The double-stranded DNA construct of claim 4 , wherein the target gene is a gene that is contained within the genome of a pathogen of the animal cell.

10. The double-stranded DNA construct of claim 1 , wherein the nucleotide sequence of the first promoter sequence is different from nucleotide sequence of the second promoter sequence.

11. The double-stranded DNA construct of claim 1 , wherein the first promoter sequence and the second promoter sequence are each operable in a eukaryotic cell.

12. The double-stranded DNA construct of claim 1 , wherein the first promoter sequence and the second promoter sequence are each operable in a prokaryotic cell.

13. A cell comprising the double-stranded DNA construct of claim 1 .

14. A prokaryotic cell comprising the double-stranded DNA construct of claim 12 .

15. The prokaryotic cell of claim 14 , wherein the target gene is a non-endogenous gene to the prokaryotic cell.

16. The prokaryotic cell of claim 15 , wherein the non-endogenous gene is a gene that is contained within the genome of an insect cell.

17. A process for producing a nucleic acid molecule comprising culturing a cell transfected with the double-stranded DNA construct of claim 1 under conditions such that the cell produces the nucleic acid molecule.

18. The process of claim 17 , wherein the cell is a prokaryotic cell.

Assignees

• Commw Scient Ind Res Org

Inventors

• Graham Michael Wayne
• Rice Robert Norman
• Waterhouse Peter Michael

Classifications

• C12N2320/30

  Special therapeutic applications · CPC title

• C12N2330/51

  Specially adapted vectors · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• C12N15/85

  for animal cells · CPC title

• C12N9/503

  derived from viruses · CPC title